Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 3/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | ESRRG | P62508 | 6/20 | 0.43 |
| ▸ | ESR1 | P03372 | 4/20 | 0.43 |
| ▸ | ESRRB | O95718 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12314795 | 1.00 | CHRNB4 (0.45) | CHRNB4CHRNA3GRIN2AGRIN2BCHRNB2 | |
| Hydrochloric Acid SCHEMBL6333252 | 0.99 | ESRRG (0.44) | CHRNB4CHRNA3GRIN2AGRIN2BCHRNB2 | |
| SCHEMBL7061296 | 0.85 | HTR6 (0.49) | CHRNB4CHRNA3GRIN2BCHRNB2CHRNA4 | |
| SCHEMBL7161658 | 0.82 | CHRNB2 (0.45) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL7062275 | 0.79 | SIGMAR1 (0.44) | KCNH2CHRM3ADRA1AHRH1HRH3 | |
| SCHEMBL7061308 | 0.79 | CHRNB4 (0.44) | CHRNB4CHRNA3CHRNB2CHRNA4KCNH2 | |
| SCHEMBL11447569 | 0.78 | ESRRG (0.64) | CHRNB4CHRNA3CHRNB2CHRNA4ESRRG | |
| SCHEMBL7061352 | 0.77 | CHRM3 (0.48) | CHRM3 | |
| SCHEMBL11458949 | 0.75 | ESRRG (0.61) | CHRNB4CHRNA3CHRNB2CHRNA4ESRRG | |
| SCHEMBL7061173 | 0.75 | CHRNB4 (0.46) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220117989-A1 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-21 | — | — | US | claimed |
| US-20180147163-A1 | COMBINATION COMPOSITIONS AND THEIR USE IN METHODS FOR TREATING OBESITY AND OBESITY-RELATED DISORDERS | HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2018-05-31 | — | — | US | claimed |
| EP-1126846-B1 | Use of a nicotine receptor agonist for the manufacture of a medicament for the treatment of obsessive compulsive disorder | CARLSSON A RESEARCH AB (SE) | 2003-08-06 | — | — | EP | claimed |
| US-20260146254-A1 | Enhancing Oligonucleotide Immunomodulatory Activity through Dianophore Long-Lasting Modification: Methods and Applications | SEGENA CORPORATION S.A. (UY) | 2026-05-28 | — | — | US | disclosed |
| EP-4622674-A1 | ENHANCING OLIGONUCLEOTIDE IMMUNOMODULATORY ACTIVITY THROUGH DIANOPHORE LONG-LASTING MODIFICATION: METHODS AND APPLICATIONS | SEGENA CORPORATION S.A. (UY) | 2025-10-01 | — | — | EP | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220117989-A1 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-21 | — | — | US | disclosed |
| US-10568852-B2 | Combination compositions and their use in methods for treating obesity and obesity-related disorders | HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-02-25 | — | — | US | disclosed |
| US-20180147163-A1 | COMBINATION COMPOSITIONS AND THEIR USE IN METHODS FOR TREATING OBESITY AND OBESITY-RELATED DISORDERS | HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180110768-A1 | METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS | PARKINSON'S INSTITUTE | 2018-04-26 | — | — | US | disclosed |
| US-20160235732-A1 | METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS | PARKINSON'S INSTITUTE | 2016-08-18 | — | — | US | disclosed |
| CN-1635877-A | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NEUROSEARCH AS (DK) | 2005-07-06 | — | — | CN | disclosed |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | ANIONA APS (DK) | 2004-05-13 | — | — | US | disclosed |
| EP-1358177-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NeuroSearch A/S (DK) | 2003-11-05 | — | — | EP | disclosed |
| EP-1126846-B1 | Use of a nicotine receptor agonist for the manufacture of a medicament for the treatment of obsessive compulsive disorder | CARLSSON A RESEARCH AB (SE) | 2003-08-06 | — | — | EP | disclosed |
| EP-0874818-B1 | NOVEL SUBSTITUTED ARYL COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | MERCK & CO INC (US) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002030405-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | WO | disclosed |
| US-6316490-B1 | FOR THERAPY OF PARKINSON'S DISEASE, ALZHEIMER'S DISEASE, DEMENTIA, CONTROLLING PAIN | MERCK & CO., INC. | 2001-11-13 | — | — | US | disclosed |
| EP-1126846-A1 | USE OF A NICOTINE RECEPTOR AGONIST IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER | A Carlsson Research AB (SE) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025783-A1 | USE OF A NICOTINE RECEPTOR AGONIST IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER | A CARLSSON RESEARCH AB (SE) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568852-B2 | Combination compositions and their use in methods for treating obesity and obesity-related disorders | FABP4, LIPC, GPR119 | CHRNB4 1944/4885CHRNA3 1071/4885GRIN2A 662/4885 |
| US-20180147163-A1 | COMBINATION COMPOSITIONS AND THEIR USE IN METHODS FOR TREATING OBESITY AND OBESITY-RELATED DISORDERS | FABP4, LIPC, GPR119 | CHRNB4 1944/4885CHRNA3 1071/4885GRIN2A 662/4885 |
| US-20180110768-A1 | METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS | CHRNA5, CHRM3, CHRM5 | CHRNB4 16/4885CHRNA3 8/4885GRIN2A 71/4885 |
| US-20160235732-A1 | METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS | CHRNA5, CHRM3, CHRM5 | CHRNB4 16/4885CHRNA3 8/4885GRIN2A 71/4885 |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | TAAR5, CHRNA5, CHRNA4 | CHRNB4 18/4885CHRNA3 5/4885GRIN2A 54/4885 |
| US-20220117989-A1 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | EYA3, RB1, ALDH1A2 | CHRNB4 157/4885CHRNA3 161/4885GRIN2A 1960/4885 |
| US-20260146254-A1 | Enhancing Oligonucleotide Immunomodulatory Activity through Dianophore Long-Lasting Modification: Methods and Applications | CD44, ADAR, TLR9 | CHRNB4 696/4885CHRNA3 718/4885GRIN2A 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.